Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now
Close

Corcept Therapeutics Incorporated (CORT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Corcept's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
22.45 -0.54    -2.35%
23/02 - Closed. Currency in USD ( Disclaimer )
After Hours
22.46
0.01
0.04%
17:19:23 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 829,680
  • Bid/Ask: 20.54 / 23.35
  • Day's Range: 22.37 - 23.07
Corcept 22.45 -0.54 -2.35%

Corcept Therapeutics Incorporated Company Profile

 
Get an in-depth profile of Corcept Therapeutics Incorporated, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

352

Equity Type

ORD

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing’s syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Contact Information

Address 149 Commonwealth Drive
Menlo Park, 94025
United States
Phone 650 327 3270
Fax -

Top Executives

Name Age Since Title
Edo Ronald De Kloet - - Member of Scientific Advisory Board
K. Ranga Rama Krishnan 64 - Member of Scientific Advisory Board
Florian Holsboer - - Member of Scientific Advisory Board
Ned H. Kalin - - Member of Scientific Advisory Board
Charles B. Nemeroff 71 - Member of Scientific Advisory Board
James N. Wilson 77 1999 Independent Chairman
Bruce S. McEwen - - Member of Scientific Advisory Board
Joseph K. Belanoff 64 1999 Co-Founder, President, CEO & Director
Kimberly Park 57 2019 Independent Director
Gillian M. Cannon 57 2020 Independent Director
Daniel N. Swisher 58 2015 Independent Director
George Leonard Baker 78 1999 Independent Director
David L. Mahoney 67 2004 Independent Director
Gregg H. Alton 55 2020 Independent Director
Joshua M. Murray - 2021 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CORT Comments

Write your thoughts about Corcept Therapeutics Incorporated
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Carlos Andres
Carlos Andres Nov 18, 2020 11:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bullish?
Carlos Andres
Carlos Andres Nov 18, 2020 11:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yes, I was right :-)
Tristan Newman
Tristan Newman Apr 23, 2020 2:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Cort seems to be doing alright now while other biotechs got spooked by the Gilead news. Anyone know why that is?
Tristan Newman
Tristan Newman Apr 23, 2020 2:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Shooting up like a rocket this morning. I'm not complaining, but seriously: what gives?
Sergio GR
Sergio GR Feb 05, 2019 10:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Lol it lost 5% in one second what happened?
Sergio GR
Sergio GR Feb 05, 2019 10:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
10%*
Trevor Headlee
Trevor Headlee Nov 03, 2017 11:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Doesn't make any sense.. Cort had a record quarter. Their best quarter ever
Trevor Headlee
Trevor Headlee Nov 01, 2017 3:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hope we beat on earnings tomorrow
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email